Octreotide Bioindustria L.I.M.

Octreotide, the active ingredient in Octreotide Bioindustria L.I.M., is a somatostatin analog presented as a strength/form for injection use. It regulates hormone secretion and is employed in the management of certain endocrine disorders in adults.

GNH USA supplies Octreotide Bioindustria L.I.M. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octreotide acts on neuroendocrine pathways and is used in several clinically recognised indications: - Acromegaly: reduces growth hormone and IGF‑1 levels, helping control disease activity. - Carcinoid syndrome: lessens flushing and diarrhoea by inhibiting serotonin release. - VIPoma-associated diarrhea: improves symptoms by blocking VIP‑mediated intestinal secretion. - Preventing postoperative pancreatic fistula after pancreatic surgery : reduces the risk of fistula development . - Control of bleeding from gastro‑intestinal tumours : provides haemostatic control when conventional methods fail .

Octreotide may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Abdominal pain: cramping or discomfort in the abdomen. - Diarrhoea: loose stools occurring intermittently. - Injection site reactions: redness, swelling or bruising at the site of administration. - Headache: transient mild headache. - Hyperglycaemia: elevated blood glucose levels, particularly in diabetic patients.

Serious or Rare Side Effects: - Gallbladder disease: formation of gallstones or biliary sludge. - Pancreatitis: inflammation of the pancreas. - Severe hypoglycaemia: marked low blood glucose, especially with concomitant insulin therapy. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals. - Acute renal failure: sudden loss of kidney function.

When using Octreotide, clinicians should consider several safety aspects: - Monitor glucose: regular blood‑glucose monitoring is advised, especially in diabetic patients. - Assess gallbladder: periodic imaging may be warranted for patients on long‑term therapy. - Evaluate cardiac function: patients with known arrhythmias should be observed. - Review concomitant meds: check for drugs that affect glucose or gastrointestinal motility. - Adjust in renal impairment: dose may need modification in severe renal dysfunction. Store at ambient temperature: keep in original container, protect from moisture and light.

Octile ​   

---